ASH Hypertension Accreditation Program
In June 2009 the Society launched of a new educational initiative in hypertension and related cardiovascular disease – the ASH Hypertension Accreditation Program – to enhance the level of education of health care providers, pharmaceutical sales representatives, medical journalists and other disseminators of health care information.
The ASH Hypertension Accreditation Program is based on the Society’s Clinical Hypertension Review Course, which emphasizes state-of-the-art scientific principles and evidence-based clinical practice. The content of the Program focuses on epidemiology, pathophysiology, disease mechanisms, antihypertensive drug classes, how to evaluate a clinical trial, how to evaluate a patient for hypertension, and clinical trials for both hypertension alone and with co-morbid conditions. The Program also includes patient case presentations which enhance the didactic educational content and allow opportunity for interaction between registrants and faculty members.
To date the Society has had approximately 1,200 Daiichi Sankyo Inc. sales representatives take the course. Daiichi Sankyo is the first pharmaceutical company to have its sales force enrolled for the ASH Hypertension Accreditation Program. To become ASH Accredited, sales representatives complete approximately 10 hours of home study prior to the live course, 13 hours of intense classroom training over 2 ½ days, six hours of homework during the training program, and pass a 1 ½ hour written exam developed and administered by ASH.
Upon successful completion of the course , representatives receive the ASH Accreditation symbol on their business card, as well as pin with the logo, and a brochure explaining the Society and this Program to be given to their physician customers.
Currently the Program is being marketed to other pharmaceutical companies, and is being developed for Primary Care Practitioners, International Physicians, PharmDs, Nurse Practitioners and Physician Assistants.